首页|123I及其标记化合物在核医学中的应用进展

123I及其标记化合物在核医学中的应用进展

扫码查看
123I是用于甲状腺疾病诊断的放射性核素,其半衰期约13.2 h,可以用于对患者进行甲状腺摄碘率测定,在甲状腺组织和甲状腺癌转移显像中具有重要价值.123I及其标记化合物对患者造成的辐射较小,通常通过胶囊或静脉注射给药,常用于甲状腺功能图像的获取和功能性疾病的诊断.123I在医学影像领域中应用广泛,尤其是在神经系统和心脏系统相关疾病的诊断中发挥了重要作用,如123I可以用于帕金森病等神经退行性疾病的诊断,也常用于心脏功能的评估,特别是冠心病或心肌缺血的诊断.笔者通过梳理近10年相关领域的研究进展,对123I目前在临床上的应用及其价值进行综述,为促进123I在临床显像中的应用提供帮助.
Application progress of 123I and its labeled compounds in nuclear medicine
123I is a radionuclide for diagnosing thyroid diseases.Its half-life of approximately 13.2 hours is suitable to perform thyroid radioiodine uptake measurement on the patients,and it has important value in thyroid tissue and thyroid cancer metastases imaging.123I and its labeled compounds has a lower radiation burden for patients and is usually administered in capsule form or by intravenous injection for obtaining functional thyroid images and diagnosing functional diseases.Additionally,it has important applications in the field of medical imaging,particularly playing a significant role in the diagnosis of neurological and cardiovascular diseases.For example,123I can be used in the diagnosis of neurodegenerative diseases such as Parkinson's disease,and it is also commonly utilized to assess cardiac function,especially in the diagnosis of coronary artery disease or myocardial ischemia.By reviewing the research advancements in the relevant field over the past decade,the authors summarize the current clinical applications and value of 123I,aiming to contribute to the promotion of its use in clinical imaging.

Iodine radioisotopesRadionuclide imagingThyroid diseasesCardiac diseasesNeurological diseases

李亚敏、章斌

展开 >

苏州大学附属第一医院核医学科,苏州 215006

碘放射性同位素 放射性核素显像 甲状腺疾病 心脏疾病 神经系统疾病

2024

国际放射医学核医学杂志
中华医学会 中国医学科学院放射医学研究所

国际放射医学核医学杂志

CSTPCD
影响因子:0.227
ISSN:1673-4114
年,卷(期):2024.48(10)